Table 1.
Correlation between PSMD3 gene expression and Clinicopathological parameters of breast cancer using TCGA data (n = 1212).
| Parameters | Categories | PSMD3 Low mRNA(n) | PSMD3 High mRNA(n) | p-Value |
|---|---|---|---|---|
| HER2 status | Positive | 52 | 133 | 0.000 *** |
| Negative | 164 | 163 | ||
| NA = 700 | ||||
| ER status | Positive | 151 | 205 | 0.874 |
| Negative | 65 | 91 | ||
| †NA = 700 | ||||
| TNBC | TNBC | 49 | 49 | 0.082 |
| Non-TNBC | 167 | 247 | ||
| †NA = 700 | ||||
| Tumor size | T1 | 173 | 135 | 0.000 *** |
| T2 | 340 | 366 | ||
| T3 | 75 | 75 | ||
| T4 | 6 | 30 | ||
| †NA = 12 | ||||
| Node | N0 | 288 | 273 | 0.787 |
| N1 | 203 | 213 | ||
| N2 | 63 | 69 | ||
| N3 | 53 | 50 | ||
| Stage | I | 120 | 89 | 0.036 * |
| II | 343 | 348 | ||
| III | 130 | 148 | ||
| IV | 13 | 21 | ||
ER, Estrogen receptor; HER2, human epidermal growth factor2; TNBC, triple-negative BC; † NA, not given. Clinicopathological parameters were assessed using Chi-square analysis. * p < 0.05, *** p < 0.001. PSMD3 low vs PSMD3 high based on the mean level of PSMD3.